scholarly journals Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time

Hepatology ◽  
2009 ◽  
Vol 49 (6) ◽  
pp. 1859-1867 ◽  
Author(s):  
Dar-In Tai ◽  
Shi-Ming Lin ◽  
I-Shyan Sheen ◽  
Chia-Ming Chu ◽  
Deng-Yn Lin ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Alanine Aminotransferase ◽  
Hepatitis B Surface Antigen ◽  
Hepatitis B E Antigen ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Over Time

scholarly journals Long-Term Outcome after Hepatitis B Surface Antigen Seroclearance in Patients with Chronic Hepatitis B

2006 ◽  
Vol 119 (1) ◽  
pp. 71.e9-71.e16 ◽  
Author(s):  
Yasuji Arase ◽  
Kenji Ikeda ◽  
Fumitaka Suzuki ◽  
Yoshiyuki Suzuki ◽  
Satoshi Saitoh ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Term Outcome ◽  
Long Term Outcome

Long-Term Outcome of Renal Transplantation in Hepatitis B Surface Antigen-Positive Patients in Cyclosporin Era

1997 ◽  
Vol 17 (5) ◽  
pp. 440-444 ◽  
Author(s):  
T. Yagisawa ◽  
H. Toma ◽  
K. Tanabe ◽  
N. Ishikawa ◽  
N. Tokumoto ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Term Outcome ◽  
Long Term Outcome

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa

Hepatology ◽  
1997 ◽  
Vol 26 (5) ◽  
pp. 1338-1342 ◽  
Author(s):  
G Fattovich ◽  
G Giustina ◽  
G Realdi ◽  
R Corrocher ◽  
S W Schalm ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Interferon Alfa ◽  
Hepatitis B E Antigen ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Compensated Cirrhosis

scholarly journals Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy

2019 ◽  
Vol 8 (11) ◽  
pp. 1892
Author(s):  
Lin ◽  
Liu ◽  
Hsu ◽  
Lin ◽  
Chiu ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Hepatitis B ◽  
Fatty Liver ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Significant Risk ◽  
Diabetic Patients ◽  
Depth Analysis ◽  
Over Time

Insulin resistance associated disorders (IRAD), including prediabetes, type 2 diabetes mellitus (T2DM), and fatty liver are significant risk factors of liver-related death in chronic hepatitis B (CHB). However, their relationship remains unclear. We aimed to evaluate how IRAD influence the kinetics of serum hepatitis B surface antigen (HBsAg) in patients with CHB during long-term entecavir treatment. We enrolled 140 patients with CHB receiving at least 3 years of consecutive entecavir treatment in this retrospective study. A linear mixed effects model was adopted to examine the effects of variables and their interaction over time on the HBsAg trajectory. Furthermore, we acquired cytokine profiles and baseline fibrosis-4 index (FIB-4) scores for in-depth analysis. The median treatment time was 6.90 (4.47–9.01) years. Multivariate analysis revealed that older patients or those with prediabetes or T2DM had a significantly slower HBsAg decline over time (p = 0.0001 and p < 0.0001, respectively). Conversely, advanced fatty liver engendered a more rapid HBsAg decrease (p = 0.001). Patients with prediabetes or T2DM possessed higher IP-10 levels six years after entecavir therapy (p = 0.013). Compared to patients without prediabetes or T2DM, diabetic patients had more unfavorable features at the baseline, especially higher FIB-4 scores. Prediabetes or T2DM delays the clearance of HBsAg, but advanced hepatic fatty change counterbalances the effect. Additionally, IRAD could cause hepatic sequelae in CHB through immune-metabolic pathways.

Sign in / Sign up

Export Citation Format

Share Document